Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Products, services, technology
Pharvaris has a platform of novel, potent and selective B2-receptor antagonist small molecules for the treatment of B2-receptor-mediated diseases. PHA121, the company’s most advanced program, is designed to treat all sub-types of hereditary angioedema (HAE).